安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMGN 安进

休市中 07-10 16:00:00 EDT

363.39

-0.23

-0.06%

盘后361.61

-1.78-0.49%

19:41 EDT

最高364.90	最低361.14	成交量163.26万
今开363.08	昨收363.62	日振幅1.03%
总市值1,957亿	流通市值1,951亿	总股本5.38亿
成交额5.93亿	换手率0.30%	流通股本5.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"安进","latestPrice":363.39,"timestamp":1783713600000,"preClose":363.62,"halted":0,"volume":1632641,"hourTrading":{"tag":"盘后","latestPrice":361.61,"preClose":363.39,"latestTime":"19:41 EDT","volume":128137,"amount":46563493.8204,"timestamp":1783726909463,"change":-1.78,"changeRate":-0.004898,"amplitude":0.006192},"delay":0,"changeRate":-0.0006325284637809202,"floatShares":536994627,"shares":538480671,"eps":14.368346,"marketStatus":"休市中","change":-0.23,"latestTime":"07-10 16:00:00 EDT","open":363.08,"high":364.895,"low":361.14,"amount":592902934.18293,"amplitude":0.010327,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":14.368346,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":363.62,"dividendRate":0.026583,"preHourTrading":{"tag":"盘前","latestPrice":364,"preClose":363.62,"latestTime":"09:27 EDT","volume":1141,"amount":415626.2509,"timestamp":1783690070121,"change":0.38,"changeRate":0.001045,"amplitude":0.016253},"postHourTrading":{"tag":"盘后","latestPrice":361.61,"preClose":363.39,"latestTime":"19:41 EDT","volume":128137,"amount":46563493.8204,"timestamp":1783726909463,"change":-1.78,"changeRate":-0.004898,"amplitude":0.006192},"volumeRatio":0.7561192907996329,"optionData":{"bulkOrders":[{"symbol":"AMGN","call":true,"expireDate":1789704000000,"strike":"395.0","timestamp":1783708943026,"price":6.5,"volume":1029,"amount":668850,"type":"-"}]},"impliedVol":0.3348,"impliedVolPercentile":0.9203},"requestUrl":"/m/hq/s/AMGN","defaultTab":"news","newsList":[{"id":"1187675803","title":"异动解读｜安进盘中下跌3.19%，生物科技板块整体承压叠加Tavneos欧盟撤市风险持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1187675803","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187675803?lang=zh_cn&edition=full","pubTime":"2026-07-06 22:12","pubTimestamp":1783347126,"startTime":"0","endTime":"0","summary":"7月6日，安进盘中下跌3.19%，报361.15美元/股，成交额1.13亿美元。消息面上，生物科技板块当日整体走弱，行业主要个股普遍下跌。公司层面，欧洲药品管理局此前建议撤销安进旗下Tavneos在欧盟的上市许可，认为支持该药获批的关键研究未遵守良好临床实践标准，提交数据存在不准确及误导性问题。此外，Rothschild & Co Redburn虽将安进目标价从200美元上调至220美元，但该目标仍显著低于市场一致预期的355.78美元，反映出部分机构对公司前景的谨慎态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126452752","title":"异动解读｜安进盘中上涨3.02%，赢得初步禁令阻止科罗拉多州对关节炎药物实施价格上限","url":"https://stock-news.laohu8.com/highlight/detail?id=1126452752","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126452752?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:42","pubTimestamp":1783003351,"startTime":"0","endTime":"0","summary":"7月2日，安进盘中上涨3.02%，报372.26美元/股，成交额1.08亿美元。消息面上，安进当日赢得初步禁令，成功阻止科罗拉多州对其类风湿性关节炎药物Enbrel施加价格上限。法院裁定为公司在药品定价监管博弈中提供了阶段性胜利，有效保护了Enbrel的商业收入前景。此外，近期安进基本面积极信号持续释放：一季度调整后EPS为5.15美元，超市场预期8.19%；皮下注射Tepezza三期试验达到主要终点；肺癌药物他拉妥单抗获中国批准；RBC等机构看好其多元化业务及新兴管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157117238","title":"Viridian Therapeutics高管透露，典型75公斤患者五次Lumvoa输注的批发采购成本约为45万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157117238","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157117238?lang=zh_cn&edition=full","pubTime":"2026-06-29 20:29","pubTimestamp":1782736176,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics公司高管指出，对于一名体重75公斤的典型患者而言，完成五次Lumvoa药物输注的批发采购成本大约在45万美元左右。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2089984988.USD","LU0109394709.USD","LU0289739699.SGD","BK4534","LU1061106388.HKD","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU2112291526.USD","LU0058720904.USD","BK4599","LU2468319806.SGD","LU0122379950.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0320765992.SGD","LU2242652126.USD","VRDN","IE0002141913.USD","LU2242646821.SGD","LU0868494617.USD","BK4139","AMGN","LU1983299246.USD","LU0889565916.HKD","BK4585","BK4588","IE00B4R5TH58.HKD","BK4533","LU1571399168.USD","SG9999001440.SGD","BK4581","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103973070","title":"Viridian高管表示：其甲状腺眼病药物Lumvoa五次输注定价与安进Tepezza八次输注大致持平 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1103973070","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103973070?lang=zh_cn&edition=full","pubTime":"2026-06-29 20:27","pubTimestamp":1782736031,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics公司高管在电话会议中透露，其用于治疗甲状腺眼病的药物Lumvoa，五次输注疗程的定价方案，与竞争对手安进公司旗下药物Tepezza的八次标准输注疗程总价大致相当。这一价格策略旨在为市场提供更具成本效益的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0289739699.SGD","LU1983299246.USD","LU0889565916.HKD","LU0868494617.USD","SG9999001440.SGD","BK4534","IE00BJT1NW94.SGD","BK4139","IE00B4R5TH58.HKD","LU2112291526.USD","VRDN","LU0122379950.USD","LU0109394709.USD","BK4581","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU1061106388.HKD","AMGN","LU2242646821.SGD","BK4533","LU2089984988.USD","LU2242652126.USD","LU1023059063.AUD","IE0002141913.USD","BK4599","IE00B2B36J28.USD","LU1057294990.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","BK4585","LU0058720904.USD","LU1571399168.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644924037","title":"瑞穗上调安进目标价至303美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644924037","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644924037?lang=zh_cn&edition=full","pubTime":"2026-06-17 10:57","pubTimestamp":1781665023,"startTime":"0","endTime":"0","summary":"瑞穗将安进的目标价从295美元上调至303美元，维持“跑赢大市”评级。(格隆汇)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260617/32282098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["AMGN","UDN","UUP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643223425","title":"和铂医药-B(02142)诉安进专利侵权胜诉获赔约2020.37万美元 最高可追偿三倍赔偿金","url":"https://stock-news.laohu8.com/highlight/detail?id=2643223425","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643223425?lang=zh_cn&edition=full","pubTime":"2026-06-15 08:32","pubTimestamp":1781483572,"startTime":"0","endTime":"0","summary":"经过2026年6月8日开始的陪审团庭审后，陪审团认定：安进侵犯了Grosveld专利，该侵权行为属于故意侵权， Grosveld专利有效，及 Harbour Antibodies有权获得约2020.37万美元的损害赔偿——即公司请求的全额赔偿。故意侵权的认定使Harbour Antibodies有权请求法院提高损害赔偿金额，可能包括最高三倍的损害赔偿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","LU2242646821.SGD","BK4533","LU2242652126.USD","SG9999001440.SGD","LU2468319806.SGD","LU2112291526.USD","02142","LU1571399168.USD","LU1057294990.SGD","BK4588","LU0109394709.USD","LU1023059063.AUD","LU0889565916.HKD","BK4566","BK4139","BK1583","LU0320765992.SGD","BK1574","BK1161","BK4534","LU1061106388.HKD","LU0122379950.USD","BK4581","LU0289739699.SGD","BK4585","AMGN","IE00BJT1NW94.SGD","LU0058720904.USD","IE0009355771.USD","LU0868494617.USD","LU1983299246.USD","IE0002141913.USD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101472667","title":"EMA药委会就Tavneos强化肝功能监测要求达成共识 将向医疗专业人员发布直接沟通文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1101472667","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101472667?lang=zh_cn&edition=full","pubTime":"2026-06-12 20:07","pubTimestamp":1781266039,"startTime":"0","endTime":"0","summary":"欧洲药品管理局（EMA）的药物警戒风险评估委员会（PRAC）已达成一致，将就Tavneos（avacopan）的强化肝功能监测要求，向医疗专业人员发布一份直接沟通文件。\n此举旨在进一步强调并确保对使用该药物的患者进行适当的肝脏安全性监测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","BK4599","IE0009355771.USD","BK4588","LU0320765992.SGD","BK4566","BK4585","BK4139","LU1057294990.SGD","LU2112291526.USD","IE00B2B36J28.USD","LU1571399168.USD","LU1983299246.USD","LU0109394709.USD","BK4581","LU0868494617.USD","LU2242646821.SGD","LU0122379950.USD","LU2468319806.SGD","LU1061106388.HKD","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU2242652126.USD","AMGN","SG9999001440.SGD","LU2089984988.USD","LU0889565916.HKD","BK4533","LU1023059063.AUD","LU0058720904.USD","IE00BJJMRZ35.SGD","BK4534","IE0002141913.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642259474","title":"安进(AMGN.US)聘请杜克临床研究所独立复核 力保明星药Tavneos免于退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2642259474","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642259474?lang=zh_cn&edition=full","pubTime":"2026-06-12 11:25","pubTimestamp":1781234700,"startTime":"0","endTime":"0","summary":"信中提到，杜克临床研究所自今年2月起，已启动一项“独立且完全设盲的重新裁定”，针对支持Tavneos获批的ADVOCATE后期临床研究的主要终点结果进行复核。面对重重质疑，安进在信中强调，公司认为Tavneos的获益大于风险，将药物撤市“不符合患者的最佳利益”。杜克临床研究所则对此拒绝置评。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"安进(AMGN.US)聘请杜克临床研究所独立复核 力保明星药Tavneos免于退市","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0058720904.USD","BK4139","LU2242646821.SGD","LU2089984988.USD","LU0889565916.HKD","LU2242652126.USD","IE0009355771.USD","LU1983299246.USD","LU0109394709.USD","BK4585","LU0122379950.USD","LU1023059063.AUD","LU0289739699.SGD","LU1057294990.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4581","AMGN","BK4588","LU2112291526.USD","SG9999001440.SGD","BK4566","LU0868494617.USD","IE00B2B36J28.USD","LU1571399168.USD","LU0320765992.SGD","BK4599","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4533","IE0002141913.USD","BK4534","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125954811","title":"异动解读｜安进盘中上涨3.22%，欧盟批准其小细胞肺癌新药Imdylltra持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1125954811","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125954811?lang=zh_cn&edition=full","pubTime":"2026-06-11 22:33","pubTimestamp":1781188394,"startTime":"0","endTime":"0","summary":"6月11日，安进盘中上涨3.22%，报348.62美元/股，成交额1.65亿美元。消息面上，欧盟委员会近日正式批准安进公司的Imdylltra®，用于治疗广泛期小细胞肺癌，为患者提供了新的治疗选择。该产品获批进一步拓展了安进在肿瘤领域的商业化布局，有望为公司带来新的营收增长点，市场情绪持续受此提振。安进所在的生物科技行业中，个股表现分化，其中Insmed涨3.01%，吉利德科学涨2.86%，艾伯维公司跌0.4%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153045404","title":"安进于美国糖尿病协会第86届科学会议上展示其心脏代谢产品组合新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1153045404","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153045404?lang=zh_cn&edition=full","pubTime":"2026-06-08 04:46","pubTimestamp":1780865173,"startTime":"0","endTime":"0","summary":"安进公司在美国糖尿病协会第86届科学会议上，公布了其心脏代谢产品系列的最新研究数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LU1023059063.AUD","IE00BJT1NW94.SGD","LU0122379950.USD","BK4588","AMGN","LU0868494617.USD","BK4566","IE00BJJMRZ35.SGD","BK4599","BK4139","BK4534","LU1061106388.HKD","LU0058720904.USD","LU2242652126.USD","SG9999001440.SGD","BK4581","IE00B2B36J28.USD","BK4533","LU0320765992.SGD","LU0289739699.SGD","LU2089984988.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU2242646821.SGD","LU0889565916.HKD","BK4585","IE0009355771.USD","LU1983299246.USD","LU2112291526.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU1057294990.SGD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157311090","title":"异动解读｜安进盘中上涨3.02%，欧盟批准其小细胞肺癌新药Imdylltra持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1157311090","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157311090?lang=zh_cn&edition=full","pubTime":"2026-06-06 00:44","pubTimestamp":1780677891,"startTime":"0","endTime":"0","summary":"6月6日，安进盘中上涨3.02%，报356.02美元/股，成交额4.3亿美元。消息面上，欧盟委员会近日正式批准安进公司的Imdylltra®，用于治疗广泛期小细胞肺癌，为患者提供了新的治疗选择。该产品获批进一步拓展了安进在肿瘤领域的商业化布局，有望为公司带来新的营收增长点，市场情绪持续受此提振。安进所在的生物科技行业中，个股整体表现偏暖，其中Argenx SE涨5.75%，福泰制药涨2.46%，艾伯维公司涨2.29%，吉利德科学涨1.71%，再生元制药公司涨1.65%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191021067","title":"异动解读｜安进盘中上涨3.01%，欧盟批准其小细胞肺癌新药Imdylltra","url":"https://stock-news.laohu8.com/highlight/detail?id=1191021067","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191021067?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:06","pubTimestamp":1780581992,"startTime":"0","endTime":"0","summary":"6月4日，安进盘中上涨3.01%，报346.541美元/股，成交额1.03亿美元。消息面上，欧盟委员会近日正式批准安进公司的Imdylltra®，用于治疗广泛期小细胞肺癌，为患者提供了新的治疗选择。该产品获批进一步拓展了安进在肿瘤领域的商业化布局，有望为公司带来新的营收增长点，市场情绪受此提振。安进所在的生物科技行业中，个股整体表现偏暖，其中Abivax S.A.涨7.58%，福泰制药涨3.54%，艾伯维公司涨2.19%，再生元制药公司涨1.12%，吉利德科学涨0.6%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162739507","title":"异动解读｜安进盘中上涨3.06%，欧盟批准其小细胞肺癌新药Imdylltra","url":"https://stock-news.laohu8.com/highlight/detail?id=1162739507","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162739507?lang=zh_cn&edition=full","pubTime":"2026-06-04 03:57","pubTimestamp":1780516622,"startTime":"0","endTime":"0","summary":"6月4日，安进盘中上涨3.06%，报338.31美元/股，成交额4.89亿美元。消息面上，欧盟委员会近日正式批准安进公司的Imdylltra®，用于治疗广泛期小细胞肺癌，为患者提供了新的治疗选择。该产品获批拓展了安进在肿瘤领域的商业化布局，有望为公司带来新的营收增长点，市场情绪受此提振。安进所在的生物科技行业中，个股整体表现偏暖，其中Abivax S.A.涨24.17%，再生元制药公司涨2.58%，吉利德科学涨1.06%，艾伯维公司涨1.04%，福泰制药涨0.76%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110834574","title":"欧盟委员会批准安进Imdylltra®用于广泛期小细胞肺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1110834574","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110834574?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:00","pubTimestamp":1780344012,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准安进公司的Imdylltra®，用于治疗广泛期小细胞肺癌。这一决定为患者提供了一种新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","BK4585","SG9999001440.SGD","BK4533","LU1983299246.USD","BK4599","BK4566","LU0889565916.HKD","BK4588","BK4534","LU0058720904.USD","LU1571399168.USD","LU2242652126.USD","BK4581","IE0002141913.USD","LU2089984988.USD","LU0122379950.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4139","LU2112291526.USD","IE00BJT1NW94.SGD","LU0109394709.USD","IE0009355771.USD","LU1057294990.SGD","LU1061106388.HKD","LU2468319806.SGD","IE00B2B36J28.USD","LU1023059063.AUD","LU0320765992.SGD","AMGN","LU0289739699.SGD","LU2242646821.SGD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169515854","title":"异动解读｜安进盘中下跌3.02%，报326.615美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169515854","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169515854?lang=zh_cn&edition=full","pubTime":"2026-06-01 23:18","pubTimestamp":1780327135,"startTime":"0","endTime":"0","summary":"6月1日，安进盘中下跌3.02%，报326.615美元/股，成交额1.7亿美元。安进所在的生物科技行业中，个股表现分化，其中BridgeBio Pharma跌0.25%，Revolution Medicines涨2.08%，艾伯维公司跌2.27%，Hyperliquid Strategies涨9.16%，Summit Therapeutics跌6.53%。安进公司成立于1980年，是全球领先的独立生物技术公司之一，专注于发现、开发、制造和交付创新药物，致力于对抗高度未满足医疗需求领域的疾病。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637548398","title":"罕见病明星药因死亡病例或遭美国撤市，安进中国回应：国内尚未商业化，未有患者接受治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2637548398","media":"澎湃新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637548398?lang=zh_cn&edition=full","pubTime":"2026-05-22 13:21","pubTimestamp":1779427260,"startTime":"0","endTime":"0","summary":"近期，因肝损伤相关死亡病例，美国安进公司的罕见病治疗药物阿伐可泮胶囊（中文商品名：特福尼，英文商品名：Tavneos）被美国监管部门提议撤销上市批准，而该药此前也在中国市场获批。5月22日，安进中国向澎湃新闻记者表示，在中国，阿伐可泮胶囊已于2024年11月获得中国国家药品监督管理局（NMPA）批准，但尚未商业化上市，截至目前中国尚无患者接受特福尼治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605223746529631.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223746529631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4599","LU1983299246.USD","SG9999001440.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","LU0122379950.USD","BK4139","IE00BFTCPJ56.SGD","LU0289739699.SGD","IE0009355771.USD","LU2468319806.SGD","LU2242652126.USD","LU1571399168.USD","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4585","IE00B2B36J28.USD","LU0889565916.HKD","LU2242646821.SGD","LU2089984988.USD","LU1061106388.HKD","BK4533","LU0320765992.SGD","BK4581","BK4534","BK4588","IE0002141913.USD","LU2112291526.USD","LU1023059063.AUD","BK4566","IE00BJT1NW94.SGD","LU0868494617.USD","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635303779","title":"Piper Sandler下调安进目标价至427美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635303779","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635303779?lang=zh_cn&edition=full","pubTime":"2026-05-15 11:17","pubTimestamp":1778815022,"startTime":"0","endTime":"0","summary":"Piper Sandler将安进的目标价从432美元下调至427美元，维持“增持”评级。(格隆汇)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260515/32227062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["AMGN","UUP","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146480534","title":"安进追加3亿美元美国制造投资，过去一年总投资额逼近20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146480534","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146480534?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:01","pubTimestamp":1777899680,"startTime":"0","endTime":"0","summary":"生物技术巨头安进公司宣布将向其美国制造业务追加3亿美元投资，这一举措使其在过去12个月内对美国本土生产设施的总投入达到近20亿美元。\n此次最新投资延续了安进强化国内供应链的战略布局，彰显了公司对提升生物制药产能的长期承诺。近20亿美元的资本注入将用于现代化生产设备升级和新技术平台部署，以支持创新疗法的规模化生产。\n作为全球生物制药领域的领导者，安进持续加大在美国的制造投入，这不仅有助于保障关键药品的稳定供应，也将为当地创造更多高技能就业岗位。公司表示，这项投资将进一步提升其应对未来医疗需求的能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1983299246.USD","LU0109394709.USD","LU2242646821.SGD","AMGN","LU2089984988.USD","LU2468319806.SGD","BK4139","SG9999001440.SGD","BK4588","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1061106388.HKD","LU0058720904.USD","IE00BFTCPJ56.SGD","BK4533","LU2112291526.USD","BK4566","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1023059063.AUD","LU1571399168.USD","BK4581","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU0868494617.USD","LU2242652126.USD","LU0122379950.USD","LU0320765992.SGD","IE0009355771.USD","IE0002141913.USD","LU1057294990.SGD","BK4599","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107055076","title":"安进提交Cbe-30文件修订肝毒性警示语 为Tavneos相关血管炎病例提供更详细信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1107055076","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107055076?lang=zh_cn&edition=full","pubTime":"2026-05-01 04:03","pubTimestamp":1777579396,"startTime":"0","endTime":"0","summary":"生物制药巨头安进公司近日向监管机构提交了Cbe-30类别文件，对其产品标签中的肝毒性警告内容进行了重要修订。此次更新特别针对与Tavneos相关的血管炎病例信息披露进行了强化，在原有警示基础上补充了更具临床参考价值的病例数据。这一调整体现了安进对药物安全监测的持续重视，旨在帮助医生更准确地评估用药风险收益比。公司表示将继续密切监测Tavneos在真实世界应用中的安全性表现，确保患者用药安全。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BK4139","LU2242646821.SGD","LU2089984988.USD","LU0889565916.HKD","LU2242652126.USD","IE0009355771.USD","LU1983299246.USD","LU0109394709.USD","BK4585","LU0122379950.USD","LU1023059063.AUD","LU0289739699.SGD","LU1057294990.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4581","AMGN","BK4588","LU2112291526.USD","SG9999001440.SGD","BK4566","LU0868494617.USD","IE00B2B36J28.USD","LU1571399168.USD","LU0320765992.SGD","BK4599","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4533","IE0002141913.USD","BK4534","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112223752","title":"安进计划与FDA展开沟通 坚信Tavneos展现疗效及良好获益-风险特征","url":"https://stock-news.laohu8.com/highlight/detail?id=1112223752","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112223752?lang=zh_cn&edition=full","pubTime":"2026-05-01 04:02","pubTimestamp":1777579369,"startTime":"0","endTime":"0","summary":"生物技术巨头安进公司表示，计划与美国食品药品监督管理局（FDA）进行积极沟通。该公司持续坚信，其药物Tavneos在临床应用中展现出显著疗效，并具备良好的获益-风险特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","IE0002141913.USD","LU1057294990.SGD","LU2468319806.SGD","BK4566","BK4599","LU0320765992.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","AMGN","BK4533","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU0289739699.SGD","BK4139","LU1023059063.AUD","LU1571399168.USD","LU2089984988.USD","SG9999001440.SGD","LU0109394709.USD","BK4534","LU2242646821.SGD","LU0122379950.USD","IE00BJT1NW94.SGD","LU0868494617.USD","LU2242652126.USD","LU1061106388.HKD","LU0889565916.HKD","BK4581","IE00B2B36J28.USD","LU2112291526.USD","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":-0.0288},{"period":"1month","weight":0.076},{"period":"3month","weight":0.0352},{"period":"6month","weight":0.1144},{"period":"1year","weight":0.2098},{"period":"ytd","weight":0.1102}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"安进公司于1980年在加利福尼亚成立，并于1987年成为特拉华州的一家公司。该公司发现、开发、制造和交付创新药物，以对抗世界上一些最棘手的疾病。该公司专注于高度未满足的医疗需求领域，并利用其专业知识努力寻求能够显著改善人们生活的解决方案，同时还能减轻疾病带来的社会和经济负担。该公司在40多年前帮助启动了生物技术产业，并已成长为世界领先的独立生物技术公司之一。","yearOnYearQuotes":[{"month":1,"riseRate":0.651163,"avgChangeRate":0.034336},{"month":2,"riseRate":0.488372,"avgChangeRate":0.00202},{"month":3,"riseRate":0.511628,"avgChangeRate":0.016602},{"month":4,"riseRate":0.44186,"avgChangeRate":-0.003156},{"month":5,"riseRate":0.511628,"avgChangeRate":0.022981},{"month":6,"riseRate":0.511628,"avgChangeRate":0.005534},{"month":7,"riseRate":0.772727,"avgChangeRate":0.051447},{"month":8,"riseRate":0.604651,"avgChangeRate":0.004451},{"month":9,"riseRate":0.511628,"avgChangeRate":0.002296},{"month":10,"riseRate":0.534884,"avgChangeRate":0.021538},{"month":11,"riseRate":0.627907,"avgChangeRate":0.022348},{"month":12,"riseRate":0.627907,"avgChangeRate":0.045446}],"exchange":"NASDAQ","name":"安进","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安进,AMGN,安进股票,安进股票老虎,安进股票老虎国际,安进行情,安进股票行情,安进股价,安进股市,安进股票价格,安进股票交易,安进股票购买,安进股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}